Forty-five patients (70.3%) who provided tumor samples were tested for survivin staining; however, only a small number (n = 4) had high survivin expression levels, preventing meaningful interpretation of the association between survivin levels and disease progression. The gene discussed is BIRC5; the disease is neoplasm.